HUE057657T2 - CD38-hoz és PD-L1-hez kötõdõ molekulák - Google Patents

CD38-hoz és PD-L1-hez kötõdõ molekulák

Info

Publication number
HUE057657T2
HUE057657T2 HUE17713672A HUE17713672A HUE057657T2 HU E057657 T2 HUE057657 T2 HU E057657T2 HU E17713672 A HUE17713672 A HU E17713672A HU E17713672 A HUE17713672 A HU E17713672A HU E057657 T2 HUE057657 T2 HU E057657T2
Authority
HU
Hungary
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
HUE17713672A
Other languages
English (en)
Inventor
Eugene Zhukovsky
Olivier Leger
Richard J Morse
Original Assignee
Biomunex Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomunex Pharmaceuticals filed Critical Biomunex Pharmaceuticals
Publication of HUE057657T2 publication Critical patent/HUE057657T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE17713672A 2016-03-25 2017-03-27 CD38-hoz és PD-L1-hez kötõdõ molekulák HUE057657T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305350 2016-03-25

Publications (1)

Publication Number Publication Date
HUE057657T2 true HUE057657T2 (hu) 2022-06-28

Family

ID=55646510

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17713672A HUE057657T2 (hu) 2016-03-25 2017-03-27 CD38-hoz és PD-L1-hez kötõdõ molekulák

Country Status (15)

Country Link
US (2) US11505616B2 (hu)
EP (2) EP3998285A1 (hu)
JP (2) JP7529401B2 (hu)
KR (1) KR102361412B1 (hu)
CN (2) CN109476741B (hu)
AU (1) AU2017236183B2 (hu)
CA (1) CA3022143A1 (hu)
DK (1) DK3433273T3 (hu)
ES (1) ES2906639T3 (hu)
HU (1) HUE057657T2 (hu)
PL (1) PL3433273T3 (hu)
PT (1) PT3433273T (hu)
RU (1) RU2764201C2 (hu)
SG (1) SG11201808289SA (hu)
WO (1) WO2017162890A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952951T3 (es) 2016-04-28 2023-11-07 Biomunex Pharmaceuticals Anticuerpos biespecíficos dirigidos a EGFR y HER2
SG11201906313SA (en) 2017-01-09 2019-08-27 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
JP7432365B2 (ja) * 2017-03-27 2024-02-16 ビオミューネクス・ファルマシューティカル 安定な多重特異性抗体
WO2019129644A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universität Würzburg TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
CN110573531B (zh) * 2018-01-15 2021-04-02 天境生物科技(上海)有限公司 经修饰的Cκ和CH1结构域
JP2021519610A (ja) 2018-03-30 2021-08-12 メルス ナムローゼ フェンノートシャップ 多価抗体
CA3116560A1 (en) * 2018-10-17 2020-04-23 Immunome, Inc. Exosome-targeting bispecific antibodies
SG11202105093RA (en) * 2018-12-21 2021-06-29 Hoffmann La Roche Tumor-targeted agonistic cd28 antigen binding molecules
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
KR20230162924A (ko) * 2021-01-11 2023-11-29 아디맵 엘엘씨 우선적인 사슬 페어링을 위해 조작된 변이체 ch1 도메인및 변이체 cl 도메인 및 이를 포함하는 다중-특이적 항체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
SI2511297T1 (sl) * 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
RS59399B1 (sr) * 2005-03-23 2019-11-29 Genmab As Antitela protiv cd38 za lečenje multiplog mijeloma
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2012088461A2 (en) 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
ES2952951T3 (es) 2016-04-28 2023-11-07 Biomunex Pharmaceuticals Anticuerpos biespecíficos dirigidos a EGFR y HER2
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
SG11201906313SA (en) 2017-01-09 2019-08-27 Biomunex Pharmaceuticals A polypeptide linker for preparing multispecific antibodies
JP7432365B2 (ja) * 2017-03-27 2024-02-16 ビオミューネクス・ファルマシューティカル 安定な多重特異性抗体
IL310960A (en) 2017-09-22 2024-04-01 Wuxi Biologics Ireland Ltd New bispecific polypeptide complexes
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
PL3433273T3 (pl) 2022-04-04
US20230146591A1 (en) 2023-05-11
AU2017236183B2 (en) 2024-03-07
JP7529401B2 (ja) 2024-08-06
KR20190016942A (ko) 2019-02-19
CN116284428A (zh) 2023-06-23
US11505616B2 (en) 2022-11-22
CN109476741A (zh) 2019-03-15
CA3022143A1 (en) 2017-09-28
AU2017236183A1 (en) 2018-11-15
KR102361412B1 (ko) 2022-02-09
DK3433273T3 (da) 2022-02-14
EP3998285A1 (en) 2022-05-18
CN109476741B (zh) 2023-02-24
SG11201808289SA (en) 2018-10-30
JP2019516396A (ja) 2019-06-20
JP2022116166A (ja) 2022-08-09
ES2906639T3 (es) 2022-04-19
RU2018137419A (ru) 2020-04-27
WO2017162890A1 (en) 2017-09-28
US20200010559A1 (en) 2020-01-09
EP3433273B1 (en) 2021-12-29
PT3433273T (pt) 2022-02-21
EP3433273A1 (en) 2019-01-30
RU2764201C2 (ru) 2022-01-14
RU2018137419A3 (hu) 2020-08-17

Similar Documents

Publication Publication Date Title
IL288012A (en) Antibody molecules against lag-3 and their use
IL263730A (en) Binding molecules that bind pd-l1 and lag-3
IL251563B (en) Antibody molecules to pd-l1 and their use
IL249269B (en) Tri-specific molecules and methods of using them
SG11201808289SA (en) Binding molecules to cd38 and pd-l1
SG10202109717TA (en) Cd20 binding molecules and uses thereof
IL273641B (en) Specific binding molecules for il-21 and uses thereof